Literature DB >> 34050439

Remimazolam anaphylaxis during anesthesia induction.

Kota Tsurumi1, Shinji Takahashi2, Yoshiyuki Hiramoto1, Kazuhiro Nagumo3, Tomonori Takazawa3, Yoichiro Kamiyama1.   

Abstract

Anaphylactic shock is a potentially lethal complication during anesthesia and requires appropriate management to save the patient's life. We report a 32-year-old man who developed anaphylaxis during induction of general anesthesia with remimazolam for hand surgery. He received general anesthesia with midazolam 4 weeks before. This time facial flushing followed by a decrease of peripheral oxygen saturation (SpO2) and blood pressure occurred 2 min after starting continuous remimazolam infusion at 6 mg/kg/h. Hypotension and SpO2 were recovered by repeated administration of adrenaline. Despite no increase of serum tryptase levels, intradermal allergy tests 4 weeks postoperatively revealed that remimazolam and midazolam were positive, suggesting remimazolam as a causative agent for anaphylaxis. In the previous surgery, midazolam, which has a similar structure to remimazolam, may have caused sensitization. This is probably the first case report of anaphylaxis caused by remimazolam.
© 2021. Japanese Society of Anesthesiologists.

Entities:  

Keywords:  Anaphylactic shock; Anaphylaxis; Anesthesia; Remimazolam

Year:  2021        PMID: 34050439     DOI: 10.1007/s00540-021-02934-8

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  1 in total

1.  Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice.

Authors:  P M Mertes; J M Malinovsky; L Jouffroy; W Aberer; I Terreehorst; K Brockow; P Demoly
Journal:  J Investig Allergol Clin Immunol       Date:  2011       Impact factor: 4.333

  1 in total
  4 in total

1.  Remimazolam anaphylaxis confirmed by serum tryptase elevation and skin test.

Authors:  M Yamaoka; K Kuroda; N Matsumoto; Y Okazaki; E Minami; C Yamashita; T Kurasako
Journal:  Anaesth Rep       Date:  2022-05-05

Review 2.  Efficacy and Safety Profile of Remimazolam for Sedation in Adults Undergoing Short Surgical Procedures.

Authors:  Yasuhiro Morimoto
Journal:  Ther Clin Risk Manag       Date:  2022-02-02       Impact factor: 2.423

3.  Cardiac Arrest Following Remimazolam-Induced Anaphylaxis: A Case Report.

Authors:  Yudai Hasushita; Megumi Nagao; Yoshihide Miyazawa; Kazuma Yunoki; Hiroyuki Mima
Journal:  A A Pract       Date:  2022-09-23

Review 4.  Profile of Remimazolam in Anesthesiology: A Narrative Review of Clinical Research Progress.

Authors:  Mi Wang; Xian Zhao; Pengfei Yin; Xiuxia Bao; Hongli Tang; Xianhui Kang
Journal:  Drug Des Devel Ther       Date:  2022-10-03       Impact factor: 4.319

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.